Corvus Pharmaceuticals, Inc. (CRVS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.04: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 1.89; Below-average business quality.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is... Read more
Sell if holding. Engine safety override at $15.04: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 1.89; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 8.7% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.04: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 1.89; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $13.98. Score 4.8/10, moderate confidence.
Take-profit target: $29.00 (+92.9% upside). Prior stop was $13.98. Stop-loss: $13.98.
Quality below floor (1.6 < 4.0).
Corvus Pharmaceuticals, Inc. trades at a P/E of N/A (forward -19.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
13 analysts cover CRVS with a consensus score of 4.3/5. Average price target: $33.
What does Corvus Pharmaceuticals, Inc. do?Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product...
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.